Source: International Congress 2016 – Clinical aspects of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Sanja Pleština (Zagreb, Croatia), Sanja Pleština, Ana Koši Kunac, Silvana Smojver-Jezek, Marko Jakopovic, Miroslav Samarzija. The proportion of EGFR+ NSCLC patients never treated with TKI – A single institution Croatian experience. Eur Respir J 2016; 48: Suppl. 60, 2810

Member's Comments

No comment yet.

Related content which might interest you: Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer? Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy? Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Mortality in asymptomatic vs. symptomatic patients surgically treated for non-small cell lung cancer (NSCLC) Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013 Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Metaanalysis of ROS1-positive lung cancer cases Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy Source: Annual Congress 2013 –Genetics and genomics of lung disease Year: 2013 Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 A single centre review of palliative chemotherapy in newly diagnosed stage IIIb and IV lung cancer patients with good performance status Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003 Locally advanced and metastatic lung cancer management delay: Tunisian department experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016